Li Jin-Ming, Zhao Rong-Hua, Li Shao-Tang, Xie Cai-Xia, Jiang Hong-Hua, Ding Wen-Jun, Du Peng, Chen Wei, Yang Ming, Cui Long
Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Saudi Med J. 2012 Jan;33(1):24-9.
To detect 4 MicroRNA (miRNA) in the stool samples of colorectal cancer (CRC) patients to determine whether these miRNAs could be biomarkers in CRC screening or treatment.
A retrospective comparison study was carried out in the Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China from September 2009 to March 2011. We detected 4 miRNAs (miR-143, miR-145, miR-21, and miR-106a) in the stool samples of 38 CRC patients and 13 healthy individuals. Total RNA from the stool samples was extracted using the EZNA TM stool RNA kit R6828-01. The miRNA quantification was carried out using TaqMan miRNA assays and the TaqMan Gene Expression Master Mix.
The expression levels of miR-143 and miR-145 in the stool of the CRC patients were lower than in those of the healthy persons (p<0.005, median of 2-∆∆ct). No statistically significant difference was found in the expression levels of both miR-21 and miR-106a between the stool of CRC patients and those of the healthy persons (p>0.05).
The detection of fecal miRNAs is a potential method for CRC diagnosis or screening. Particularly, the down-regulation of fecal miR-143 and miR-145 could be a potential marker for CRC.
检测结直肠癌(CRC)患者粪便样本中的4种微小RNA(miRNA),以确定这些miRNA是否可作为CRC筛查或治疗的生物标志物。
2009年9月至2011年3月在上海交通大学医学院附属新华医院结直肠外科进行了一项回顾性对比研究。我们检测了38例CRC患者和13名健康个体粪便样本中的4种miRNA(miR-143、miR-145、miR-21和miR-106a)。使用EZNA TM粪便RNA试剂盒R6828-01从粪便样本中提取总RNA。使用TaqMan miRNA检测试剂盒和TaqMan基因表达主混合试剂进行miRNA定量分析。
CRC患者粪便中miR-143和miR-145的表达水平低于健康人(p<0.005,2-∆∆ct中位数)。CRC患者与健康人粪便中miR-21和miR-106a的表达水平均无统计学显著差异(p>0.05)。
粪便miRNA检测是CRC诊断或筛查的一种潜在方法。特别是,粪便中miR-143和miR-145的下调可能是CRC的潜在标志物。